Post on 23-Oct-2019
transcript
ESMO Preceptorship Programme
Metastatic castration sensitive prostate cancer
Dr B. Rakesh Reddy MD DM ECMO
Consultant Medical Oncologist
Mahatma Gandhi Cancer Hospital & Research Institute
Visakhapatnam, India
Prostate – Singapore – 21-22nd November, 2018
ESMO PRECEPTORSHIP PROGRAMME
Case
� 66yr old farmer.
� Diabetic, no other comorbidities
� Presented with Lower urinary tract symptoms – Dysuria, straining to pass urine
� Ultrasound abdomen revealed a prostatic mass;MRI pelvis revealed extraprostatic extension; Serum PSA was 18ng/ml
� Underwent TRUS guided sextant biopsy of prostate mass
� Diagnosed with prostate adenocarcinoma, high risk. Gleason’s score 8 (5+3)
� No metastasis on bone scan, CT abdomen and chest X-ray
ESMO PRECEPTORSHIP PROGRAMME
Treatment
� Post 3 doses of monthly Leuprolide 7.5mg, he was given EBRT
(74Gy in 37 fractions) by IGRT. Leuprolide was continued for a
total of two years.
� He had initial symptom resolution and PSA normalized.
� His tolerance to treatment was good
� Lost to follow up after 4 years of baseline treatment
� 6 years after completion of treatment, he developed lower
urinary tract symptoms and acute onset of severe pain in the left
upper arm.
ESMO PRECEPTORSHIP PROGRAMME
Evaluation
� PSA 368 ng/ml
� PSMA PET/CT was done
PSMA avid lesions ( s/o metastasis) in prostate bed, pelvic nodes, para aortic nodes
Multiple dorso-lumabr vertebrae and large destructive lesion in the left proximal humerus
ESMO PRECEPTORSHIP PROGRAMME
Treatment
� Presently 74 years. No other co-morbidities except for well
controlled diabetes. ECOG PS 2.
� Metastatic castration sensitive prostate cancer
� High disease volume - multiple bones involved including
bones outside lumbar vertebrae and pelvic bones
� Treatment options??
ESMO PRECEPTORSHIP PROGRAMME
Treatment
� Options considered:
1. castration – medical or surgical.
2. castration + docetaxel or abiraterone
� Treatment given: palliative RT to the humerus lesion; bilateral orchidectomy, 3 weekly Docetaxel (PS improved with pain control prior to starting doce) and monthly zoledronic acid.
� Latest value of PSA is 0.08ng/ml at 5 months of treatment
� Got a total of 6 doses of docetaxel. Patient developed grade 3 neutropenia and grade 2 neuropathy.
ESMO PRECEPTORSHIP PROGRAMME
Questions to consider
� Follow up after treatment of high risk localized
prostate cancer
� Mode of castration
� Addition of docetaxel or abiraterone in first line
treatment of metastatic castration sensitive prostate
cancer
� Low dose abiraterone with food in this setting
ESMO PRECEPTORSHIP PROGRAMME
DISCLAIMER
� CONFLICT OF INTEREST – NONE
� DISCLOSURES – NONE TO DECLARE